Roche's Lucentis sales gain signals positive for Regeneron
This article was originally published in Scrip
Executive Summary
Sales of Roche’s eye drug Lucentis are rebounding after losing ground to Regeneron Pharmaceuticals’ Eylea, which hit the US market in late 2011.